Project Term: 18 months, Ended 2017
Grant Amount: $20,000
This project seeks to support effective, office-based treatment of opioid addiction by physicians (opioids include drugs such as heroin and oxycodone). Buprenorphine is an opioid that is used in medications that are approved for office-based treatment of opioid addiction, such as Suboxone. Providers must receive special approval from the Drug Enforcement Agency (DEA) to use buprenorphine-containing products for this purpose. This proposal will engage primary care providers in developing, piloting, and evaluating a practical, best-practices guide grounded in the challenges unique to Montana.